259 completed, 33 terminated, 19 unknown, 15 recruiting. 355 Phase 2, 29 Phase 1, 16 Phase 3.
Follow Psoriasis: new trials by email Literature Review of Psoriasis trials Research Report on Psoriasis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Comparative Study on Unani Formulation Vs Active Control in Plaque Psoriasis Marham Asfedaj, Mundij wa Mushil Sawda (Unani Oral decoction), Coal tar 1% & Salicylic acid 3 % solution - Chronic Plaque Psoriasis, Plaque Psoriasis | Phase 2 | Not yet recruiting | National Institute of Unani Medicine, Bengaluru | 54 | 2027-04-01 | 2026-09-25 |
| Evaluation of Safety and Efficacy of IRX4204 in Mild to Moderate Plaque Psoriasis IRX4204, Placebo - Psoriasis, Plaque Type Psorisis | Phase 2 | Suspended | Io Therapeutics | 20 | 2027-03-01 | 2026-11-12 |
| Extension Study of Safety and Tolerability of DDY391 in Participants With Moderate to Severe Psoriatic Arthritis (CDDY391A12201-extension) DDY391 - Moderate to Severe Psoriatic Arthritis | Phase 2 | Not yet recruiting | Novartis Pharmaceuticals | 88 | 2027-02-10 | 2026-11-06 |
| A Study to Assess Targeted Therapies for Treatment of Adults With Moderate to Severe Psoriasis Risankizumab, ABBV-295, ABBV-295 Placebo - Moderate to Severe Psoriasis | Phase 2 | Not yet recruiting | AbbVie | 105 | 2026-12-03 | 2026-11-12 |
| Phase 2 Trial of FT2109 for the Treatment of Psoriatic Arthritis FT2109 Dosing Regimen 1, FT2109 Dosing Regimen 2, Matching Placebo - Psoriatic Arthritis (PsA) | Phase 2 | Not yet recruiting | Forward Therapeutics | 210 | 2026-12-01 | 2026-10-09 |
| A Study to Assess the Safety and Effectiveness of COL-5671-PRO Capsules in Adults With Moderate-to-Severe Plaque Psoriasis COL-5671-PRO, Placebo - Plaque Psoriasis | Phase 2 | Not yet recruiting | Coultreon Biopharma | 100 | 2026-10-31 | 2026-11-03 |
| A Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Moderate to Severe Psoriatic Arthritis DDY391, Placebo - Moderate to Severe Psoriatic Arthritis | Phase 2 | Recruiting | Novartis Pharmaceuticals | 220 | 2026-10-19 | 2026-11-09 |
| A Study to Investigate the Efficacy and Safety Profile of GM-XANTHO [GM-XAN003] in Patients With Psoriasis 5% GM-XANTHO [GM-XAN003], Placebo - Psoriasis | Phase 2 | Not yet recruiting | Xantho Biotechnology Co., LTD | 65 | 2026-10-01 | 2026-08-07 |
| Phase II Clinical Trial of SHR-1139 Injection in Patients With Psoriasis The SHR-1139 injection, placebo - Psoriasis | Phase 2 | Recruiting | Guangdong Hengrui Pharmaceutical Co., Ltd | 60 | 2026-08-04 | 2026-08-20 |
| A Clinical Trial of TQH3906 Capsules in the Treatment of Active Psoriatic Arthritis TQH3906 Capsule, TQH3906 Placebo Capsule, Tofacitinib Citrate Tablet 5 mg - Psoriatic Arthritis | Phase 2 | Recruiting | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | 156 | 2026-07-16 | 2026-09-02 |
| Oral CBP-0276 or Placebo in Adults With Active Psoriatic Arthritis (PsA) CBP-0276 capsules 100mg, Placebo - Arthritic Psoriasis | Phase 2 | Not yet recruiting | Clarent Biopharma, Inc. | 240 | 2026-07-01 | 2026-07-16 |
| A Study to Evaluate D-2570 in Participants With Moderate to Severe Plaque Psoriasis D-2570 Tablet, Placebo Tablets - Psoriasis | Phase 2 | Recruiting | InventisBio Co., Ltd | 75 | 2026-06-03 | 2026-07-09 |
| Trial of HSK44459 Cream for the Management Plaque Psoriasis HSK44459 Cream, Vehicle - Psoriasis | Phase 1 / Phase 2 | Active not recruiting | Haisco Pharmaceutical Group Co., Ltd. | 180 | 2026-05-22 | 2026-06-08 |
| Study to Evaluate Tulisokibart in Adults With Psoriatic Arthritis (MK-7240-015) Tulisokibart, Placebo - Psoriatic Arthritis | Phase 2 | Active not recruiting | Merck Sharp & Dohme LLC | 140 | 2026-04-20 | 2026-10-20 |
| A Clinical Trial of TQH2929 Injection in Patients With Acute Flare-up of Generalized Pustular Psoriasis TQH2929 Injections, TQH2929 Placebo - Generalized Pustular Psoriasis | Phase 2 | Terminated | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 36 | 2026-03-19 | 2026-08-03 |
| A Phase II Study to Evaluate the Efficacy and Safety of D-2570 in Subjects With Active Psoriatic Arthritis D-2570, Placebo - PsA (Psoriatic Arthritis) | Phase 2 | Recruiting | InventisBio Co., Ltd | 222 | 2026-01-16 | 2026-04-22 |
| A Study to Evaluate the Efficacy and Safety of JNJ-88545223 for the Treatment of Participants With Active Psoriatic Arthritis JNJ-88545223, Placebo - Arthritis, Psoriatic | Phase 2 | Active not recruiting | Janssen Research & Development, LLC | 157 | 2026-01-15 | 2026-11-03 |
| A Study of Picankibart in Patients With Active Psoriatic Arthritis Placebo, Picankibart - Psoriatic Arthritis | Phase 2 / Phase 3 | Recruiting | Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. | 222 | 2025-12-18 | 2026-03-20 |
| Safety and Efficacy of Lactobacillus Plantarum for Psoriasis: A Randomized Double-Blind Placebo-Controlled Trial Lactobacillus plantarum, inactivated Lactobacillus plantarum - Psoriasis, Lactobacillus Plantarum | Phase 2 | Recruiting | Shenzhen People's Hospital | 184 | 2025-12-15 | 2025-12-24 |
| Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty Methotrexate, Sulfasalazine, Hydroxychloroquine - Rheumatic Disease | Phase 2 | Recruiting | NYU Langone Health | 80 | 2025-12-12 | 2026-07-09 |
Showing 20 of 355. Sign in to see all of them.
Arthritis, Psoriatic (65) · Skin Diseases (19) · Arthritis, Rheumatoid (15) · Arthritis (11) · Plaque, Amyloid (9) · Spondylitis, Ankylosing (9) · Inflammation (7) · Lymphoma, Follicular (6) · Pruritus (6) · Dermatitis, Atopic (5) · Eczema (5) · Bronchiolitis Obliterans Syndrome (4) · Osteoarthritis (4) · Crohn Disease (3)
Skin Diseases, Papulosquamous (354) · Skin and Connective Tissue Diseases (353) · Skin Diseases (336) · Bone Diseases (67) · Musculoskeletal Diseases (67) · Spinal Diseases (67) · Joint Diseases (66) · Spondylitis (66) · Spondylarthritis (64) · Spondylarthropathies (64) · Arthritis (57) · Immune System Diseases (28) · Pathological Conditions, Signs and Symptoms (24) · Connective Tissue Diseases (16)
Adalimumab (11) · apremilast (10) · calcipotriene (10) · bimekizumab (9) · risankizumab (9) · secukinumab (8) · tofacitinib (7) · Methotrexate (6) · Ustekinumab (6) · spesolimab (6) · Clobetasol (5) · Etanercept (5) · Roflumilast (5) · guselkumab (5) · Betamethasone (4)
Pfizer (12) · Boehringer Ingelheim (11) · AbbVie (9) · Amgen (9) · Novartis Pharmaceuticals (9) · Abbott (6) · Almirall, S.A. (6) · Bausch Health Americas, Inc. (6) · Bristol-Myers Squibb (6) · LEO Pharma (6) · University of Medicine and Dentistry of New Jersey (6) · GlaxoSmithKline (5) · Janssen Research & Development, LLC (5) · UCB Biopharma SRL (5) · Galderma R&D (4)
United States (177) · Germany (72) · Canada (67) · Poland (48) · China (35) · Czechia (25) · Spain (25) · Hungary (24) · United Kingdom (24) · Japan (23) · France (18) · Bulgaria (16) · Russia (16) · Australia (15) · Belgium (14)
Binu J Alexander, MD (3) · Melissa Magliocco, MD (3) · Alice Gottlieb, MD, PhD (2)
PMID 35544084, PMID 19380660, PMID 30739254, PMID 31667790, PMID 32207067, PMID 35789257, PMID 35931879, PMID 36178584, PMID 36919398, PMID 37316690, PMID 37906417, PMID 39848568, PMID 40194794, PMID 40862624, PMID 41807031, PMID 12622624, PMID 12813013, PMID 12917302, PMID 15009298, PMID 15327535, PMID 15389187, PMID 15872205, PMID 15888152, PMID 16778789, PMID 16895558, PMID 17287478, PMID 17596167, PMID 18283176, PMID 18384439, PMID 18645136, PMID 19217154, PMID 19466961, PMID 19587341, PMID 19641206, PMID 19811850, PMID 20015525, PMID 20071701, PMID 20103558, PMID 20231202, PMID 20412573, PMID 20655127, PMID 20716226, PMID 20811392, PMID 21128258, PMID 21206136, PMID 21244768, PMID 21404914, PMID 21425247, PMID 21504485, PMID 21623773
2016 (9), 2018 (9), 2017 (8), 2014 (5), 2023 (4), 2015 (3), 2025 (3), 2005 (2), 2019 (2), 2008 (1), 2009 (1), P20GM130414 (1), P60AR047782 (1), R01AR050100 (1), R33AR077495 (1)